Published in J Neurosci on April 01, 2009
Immune activation in brain aging and neurodegeneration: too much or too little? Neuron (2009) 3.76
Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron (2013) 3.43
CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J Neurosci (2009) 2.69
Inflammation, microglia, and Alzheimer's disease. Neurobiol Dis (2009) 2.44
The role of microglia in amyloid clearance from the AD brain. J Neural Transm (Vienna) (2010) 2.21
Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 2.01
CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-β phagocytosis. J Neurosci (2010) 1.88
Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J (2009) 1.73
Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic Biol Med (2010) 1.57
IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol (2010) 1.55
Microglial dysfunction in brain aging and Alzheimer's disease. Biochem Pharmacol (2014) 1.52
Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS One (2013) 1.48
Microglia and inflammation in Alzheimer's disease. CNS Neurol Disord Drug Targets (2010) 1.37
APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem (2012) 1.34
ApoE and Aβ in Alzheimer's disease: accidental encounters or partners? Neuron (2014) 1.33
Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. FASEB J (2012) 1.28
Heparan sulphate proteoglycan and the low-density lipoprotein receptor-related protein 1 constitute major pathways for neuronal amyloid-beta uptake. J Neurosci (2011) 1.28
Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid {beta} neurotoxicity in in vitro and in vivo models of Alzheimer's disease. Am J Pathol (2009) 1.27
Phagocytic clearance in neurodegeneration. Am J Pathol (2011) 1.25
Apolipoprotein E promotes β-amyloid trafficking and degradation by modulating microglial cholesterol levels. J Biol Chem (2011) 1.23
Microglia activation and anti-inflammatory regulation in Alzheimer's disease. Mol Neurobiol (2010) 1.22
Disruption of arterial perivascular drainage of amyloid-β from the brains of mice expressing the human APOE ε4 allele. PLoS One (2012) 1.22
CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS One (2009) 1.21
Microglial phagocytosis induced by fibrillar β-amyloid is attenuated by oligomeric β-amyloid: implications for Alzheimer's disease. Mol Neurodegener (2011) 1.20
Microglia function in Alzheimer's disease. Front Pharmacol (2012) 1.17
Protein aggregate spreading in neurodegenerative diseases: problems and perspectives. Neurosci Res (2011) 1.15
Differential regulation of amyloid-β endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. J Biol Chem (2012) 1.15
Neuronal clearance of amyloid-β by endocytic receptor LRP1. J Neurosci (2013) 1.13
Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Aβ uptake and degradation by astrocytes. J Biol Chem (2012) 1.13
Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques. Nat Commun (2015) 1.11
Viewing ageing eyes: diverse sites of amyloid Beta accumulation in the ageing mouse retina and the up-regulation of macrophages. PLoS One (2010) 1.10
Hippocampal expression of murine TNFα results in attenuation of amyloid deposition in vivo. Mol Neurodegener (2011) 1.10
Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow. Am J Pathol (2010) 1.09
Soluble apoE/Aβ complex: mechanism and therapeutic target for APOE4-induced AD risk. Mol Neurodegener (2014) 1.09
Immunity and inflammation in neurodegenerative diseases. Am J Neurodegener Dis (2013) 1.08
Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J Biol Chem (2013) 1.07
Progranulin is a chemoattractant for microglia and stimulates their endocytic activity. Am J Pathol (2010) 1.06
Innate immunity in Alzheimer's disease: a complex affair. CNS Neurol Disord Drug Targets (2013) 1.05
The low-density lipoprotein receptor-related protein 1 and amyloid-β clearance in Alzheimer's disease. Front Aging Neurosci (2014) 1.01
Enhancing astrocytic lysosome biogenesis facilitates Aβ clearance and attenuates amyloid plaque pathogenesis. J Neurosci (2014) 1.00
Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid-β neurotoxicity. Am J Pathol (2011) 1.00
Aβ internalization by neurons and glia. Int J Alzheimers Dis (2011) 0.99
Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? Front Aging Neurosci (2010) 0.98
Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. Mol Neurodegener (2012) 0.97
The ubiquitin proteasome system in glia and its role in neurodegenerative diseases. Front Mol Neurosci (2014) 0.96
Hematopoietic CC-chemokine receptor 2 (CCR2) competent cells are protective for the cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. Mol Med (2012) 0.96
Molecular interplay between leptin, insulin-like growth factor-1, and β-amyloid in organotypic slices from rabbit hippocampus. Mol Neurodegener (2011) 0.96
Lipoprotein lipase is a novel amyloid beta (Abeta)-binding protein that promotes glycosaminoglycan-dependent cellular uptake of Abeta in astrocytes. J Biol Chem (2010) 0.95
P2 receptors for extracellular nucleotides in the central nervous system: role of P2X7 and P2Y₂ receptor interactions in neuroinflammation. Mol Neurobiol (2012) 0.94
Sequestration of toxic oligomers by HspB1 as a cytoprotective mechanism. Mol Cell Biol (2011) 0.94
Age-dependent effect of apolipoprotein E4 on functional outcome after controlled cortical impact in mice. J Cereb Blood Flow Metab (2010) 0.93
Transcription factor p53 influences microglial activation phenotype. Glia (2011) 0.93
Forebrain microglia from wild-type but not adult 5xFAD mice prevent amyloid-β plaque formation in organotypic hippocampal slice cultures. Sci Rep (2015) 0.92
SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. Hum Mol Genet (2014) 0.90
Traumatic brain injury, microglia, and Beta amyloid. Int J Alzheimers Dis (2012) 0.90
Mechanisms of amyloid-Beta Peptide uptake by neurons: the role of lipid rafts and lipid raft-associated proteins. Int J Alzheimers Dis (2010) 0.89
Novel and rare functional genomic variants in multiple autoimmune syndrome and Sjögren's syndrome. J Transl Med (2015) 0.89
Phosphorylation of amyloid-β peptide at serine 8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymes. J Biol Chem (2012) 0.88
Nuclear translocation uncovers the amyloid peptide Aβ42 as a regulator of gene transcription. J Biol Chem (2014) 0.88
Age-related changes in synaptic markers and monocyte subsets link the cognitive decline of APP(Swe)/PS1 mice. Front Cell Neurosci (2012) 0.87
Microglial Aβ receptors in Alzheimer's disease. Cell Mol Neurobiol (2014) 0.86
Neuroprotective roles of the P2Y(2) receptor. Purinergic Signal (2012) 0.84
Aging reduces glial uptake and promotes extracellular accumulation of Aβ from a lentiviral vector. Front Aging Neurosci (2014) 0.84
Selective targeting of microglia by quantum dots. J Neuroinflammation (2012) 0.84
Glycogen synthase kinase-3 and p38 MAPK are required for opioid-induced microglia apoptosis. Neuropharmacology (2010) 0.84
Alzheimer's Disease: APP, Gamma Secretase, APOE, CLU, CR1, PICALM, ABCA7, BIN1, CD2AP, CD33, EPHA1, and MS4A2, and Their Relationships with Herpes Simplex, C. Pneumoniae, Other Suspect Pathogens, and the Immune System. Int J Alzheimers Dis (2011) 0.84
Human APOE genotype affects intraneuronal Aβ1-42 accumulation in a lentiviral gene transfer model. Hum Mol Genet (2013) 0.83
From development to dysfunction: microglia and the complement cascade in CNS homeostasis. Ageing Res Rev (2013) 0.83
Sequence-dependent internalization of aggregating peptides. J Biol Chem (2014) 0.82
Loss of interleukin receptor-associated kinase 4 signaling suppresses amyloid pathology and alters microglial phenotype in a mouse model of Alzheimer's disease. J Neurosci (2012) 0.82
Robust uptake of magnetic nanoparticles (MNPs) by central nervous system (CNS) microglia: implications for particle uptake in mixed neural cell populations. Int J Mol Sci (2010) 0.82
Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND). PLoS One (2014) 0.82
Single-walled carbon nanotubes alleviate autophagic/lysosomal defects in primary glia from a mouse model of Alzheimer's disease. Nano Lett (2014) 0.81
Mechanisms of U87 astrocytoma cell uptake and trafficking of monomeric versus protofibril Alzheimer's disease amyloid-β proteins. PLoS One (2014) 0.81
Genomic background-related activation of microglia and reduced β-amyloidosis in a mouse model of Alzheimer's disease. Eur J Microbiol Immunol (Bp) (2013) 0.81
When human immunodeficiency virus meets chemokines and microglia: neuroprotection or neurodegeneration? J Neuroimmune Pharmacol (2012) 0.81
p75NTR is mainly responsible for Aβ toxicity but not for its internalization: a primary study. Neurol Sci (2011) 0.80
Young microglia restore amyloid plaque clearance of aged microglia. EMBO J (2016) 0.80
Arf6 controls beta-amyloid production by regulating macropinocytosis of the Amyloid Precursor Protein to lysosomes. Mol Brain (2015) 0.80
The pathogenic implication of abnormal interaction between apolipoprotein E isoforms, amyloid-beta peptides, and sulfatides in Alzheimer's disease. Mol Neurobiol (2010) 0.80
TDP-43: a new player on the AD field? Exp Neurol (2012) 0.80
In vivo Differential Brain Clearance and Catabolism of Monomeric and Oligomeric Alzheimer's Aβ protein. Front Aging Neurosci (2016) 0.80
Autophagy is involved in oligodendroglial precursor-mediated clearance of amyloid peptide. Mol Neurodegener (2013) 0.80
SOLUBLE CD40 LIGAND IN DEMENTIA. Drugs Future (2009) 0.79
P2Y4 receptor-mediated pinocytosis contributes to amyloid beta-induced self-uptake by microglia. Mol Cell Biol (2013) 0.79
Distinct internalization pathways of human amylin monomers and its cytotoxic oligomers in pancreatic cells. PLoS One (2013) 0.79
P2Y receptors in Alzheimer's disease. Biol Cell (2014) 0.79
Viable mouse gene ablations that robustly alter brain Aβ levels are rare. BMC Neurosci (2010) 0.79
Activated scavenger receptor A promotes glial internalization of aβ. PLoS One (2014) 0.79
Mechanisms of Aβ Clearance and Degradation by Glial Cells. Front Aging Neurosci (2016) 0.79
Clearance of cerebral Aβ in Alzheimer's disease: reassessing the role of microglia and monocytes. Cell Mol Life Sci (2017) 0.79
Animal Models of Alzheimer's Disease: Utilization of Transgenic Alzheimer's Disease Models in Studies of Amyloid Beta Clearance. Curr Transl Geriatr Exp Gerontol Rep (2012) 0.78
Inhibiting ACAT1/SOAT1 in microglia stimulates autophagy-mediated lysosomal proteolysis and increases Aβ1-42 clearance. J Neurosci (2014) 0.78
Splenocytes derived from young WT mice prevent AD progression in APPswe/PSENldE9 transgenic mice. Oncotarget (2015) 0.78
Interaction between therapeutic interventions for Alzheimer's disease and physiological Aβ clearance mechanisms. Front Aging Neurosci (2015) 0.78
The evolving biology of microglia in Alzheimer's disease. Neurotherapeutics (2015) 0.77
A novel mouse model of Alzheimer's disease with chronic estrogen deficiency leads to glial cell activation and hypertrophy. J Aging Res (2011) 0.77
The endocytic pathway in microglia during health, aging and Alzheimer's disease. Ageing Res Rev (2016) 0.77
Targeting microglial K(ATP) channels to treat neurodegenerative diseases: a mitochondrial issue. Oxid Med Cell Longev (2013) 0.77
Inhibition of amyloid precursor protein secretases reduces recovery after spinal cord injury. Brain Res (2014) 0.76
Regulated portals of entry into the cell. Nature (2003) 15.33
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science (2005) 14.43
Microglia: a sensor for pathological events in the CNS. Trends Neurosci (1996) 12.00
ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci (2005) 11.55
Endocytosis and molecular sorting. Annu Rev Cell Dev Biol (1996) 8.83
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell (2005) 8.40
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 7.69
Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci (2007) 7.42
Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol (1999) 7.16
Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron (2006) 6.38
Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci (2007) 6.27
Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci (2007) 6.23
Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med (2006) 5.09
The many faces of actin: matching assembly factors with cellular structures. Nat Cell Biol (2007) 4.90
Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med (2003) 4.77
Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol (1990) 4.37
LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron (2004) 4.29
Macropinocytosis. Trends Cell Biol (1995) 4.03
Integrin-associated protein (CD47) and its ligands. Trends Cell Biol (2001) 3.79
Phagocytosis: elegant complexity. Immunity (2005) 3.27
Lipid rafts and caveolae as portals for endocytosis: new insights and common mechanisms. Traffic (2003) 3.25
Transferrin receptor and its recycling in HeLa cells. EMBO J (1982) 3.17
The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol (1999) 2.73
Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med (2004) 2.72
Human immunodeficiency virus type 1 entry into macrophages mediated by macropinocytosis. J Virol (2001) 2.67
A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci (2003) 2.63
Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci (2008) 2.57
Caveosomes and endocytosis of lipid rafts. J Cell Sci (2003) 2.44
High-yield isolation of murine microglia by mild trypsinization. Glia (2003) 2.39
Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med (2007) 2.32
Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. Mol Cell Biol (2007) 2.25
Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. J Neurosci (2004) 2.24
CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am J Pathol (2002) 2.22
Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest (2005) 1.94
Macropinocytosis is the endocytic pathway that mediates macrophage foam cell formation with native low density lipoprotein. J Biol Chem (2004) 1.92
Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J Neurosci (1997) 1.87
Clathrin-independent endocytosis: new insights into caveolae and non-caveolar lipid raft carriers. Biochim Biophys Acta (2005) 1.87
Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein. Proc Natl Acad Sci U S A (1992) 1.85
Scavenger receptors in neurobiology and neuropathology: their role on microglia and other cells of the nervous system. Glia (2002) 1.81
Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience (2002) 1.73
Origin, originality, functions, subversions and molecular signalling of macropinocytosis. Int J Med Microbiol (2002) 1.72
Actin, microtubules and focal adhesion dynamics during cell migration. Int J Biochem Cell Biol (2003) 1.71
Macropinocytosis: regulated coordination of endocytic and exocytic membrane traffic events. J Cell Sci (2006) 1.64
Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. Mol Biol Cell (2007) 1.61
Phagocytosis and macropinocytosis in Dictyostelium: phosphoinositide-based processes, biochemically distinct. Traffic (2001) 1.59
Rab proteins and endocytic trafficking: potential targets for therapeutic intervention. Adv Drug Deliv Rev (2003) 1.57
In vivo multiphoton imaging of a transgenic mouse model of Alzheimer disease reveals marked thioflavine-S-associated alterations in neurite trajectories. J Neuropathol Exp Neurol (2003) 1.50
Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J (2002) 1.48
Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease. Neurochem Int (2001) 1.47
Slow degradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells. J Biol Chem (1997) 1.45
Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells. J Biol Chem (1999) 1.42
Molecular size-fractionation during endocytosis in macrophages. J Cell Biol (1995) 1.40
Internalization of beta-amyloid peptide by primary neurons in the absence of apolipoprotein E. J Biol Chem (2007) 1.39
Drinking a lot is good for dendritic cells. Immunology (2006) 1.36
Thrombspondin acts via integrin-associated protein to activate the platelet integrin alphaIIbbeta3. J Biol Chem (1997) 1.34
Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov Today (2006) 1.28
The cell-selective neurotoxicity of the Alzheimer's Abeta peptide is determined by surface phosphatidylserine and cytosolic ATP levels. Membrane binding is required for Abeta toxicity. J Neurosci (2007) 1.26
Recombinant GST/CD36 fusion proteins define a thrombospondin binding domain. Evidence for a single calcium-dependent binding site on CD36. J Biol Chem (1995) 1.25
LRP in amyloid-beta production and metabolism. Ann N Y Acad Sci (2006) 1.17
Scavenging of Alzheimer's amyloid beta-protein by microglia in culture. J Neurosci Res (1996) 1.14
Signaling and invasin-promoted uptake via integrin receptors. Microbes Infect (2000) 1.14
Yersinia enterocolitica invasin triggers phagocytosis via beta1 integrins, CDC42Hs and WASp in macrophages. Cell Microbiol (2001) 1.13
Interaction of a 39 kDa protein with the low-density-lipoprotein-receptor-related protein (LRP) on rat hepatoma cells. Biochem J (1993) 1.07
A clathrin, caveolae, and dynamin-independent endocytic pathway requiring free membrane cholesterol drives HIV-1 internalization and infection in polarized trophoblastic cells. J Mol Biol (2007) 1.07
The interplay between clathrin-coated vesicles and cell signalling. Semin Cell Dev Biol (2007) 1.00
Low density lipoprotein receptor-related proteins (LRPs), Alzheimer's and cognition. Curr Drug Targets CNS Neurol Disord (2005) 0.97
Role of LRP in TGFbeta2-mediated neuronal uptake of Abeta and effects on memory. J Neurosci Res (2004) 0.92
Effect of chloroquine and leupeptin on intracellular accumulation of amyloid-beta (A beta) 1-42 peptide in a murine N9 microglial cell line. FEBS Lett (1998) 0.92
Pinocytosis as a select marker of ramified microglia in vivo and in vitro. J Histochem Cytochem (1991) 0.86
Freeze-fracture images on filipin-sterol complexes in the thyroid follicle epithelial cell of mice with special regard to absence of cholesterol at the site of micropinocytosis. Histochemistry (1981) 0.83
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science (2012) 10.42
Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron (2005) 7.53
National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke (2006) 6.94
Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature (2008) 6.89
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (2010) 6.17
The role of apolipoprotein E in Alzheimer's disease. Neuron (2009) 5.55
Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat Neurosci (2011) 5.40
Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med (2006) 5.09
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01
In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci (2003) 5.00
Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science (2009) 4.92
ApoE promotes the proteolytic degradation of Abeta. Neuron (2008) 4.75
Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol (2009) 4.71
A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol (2009) 4.59
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol (2009) 4.55
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature (2009) 4.43
ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron (2004) 4.21
Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med (2011) 4.07
Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron (2008) 3.98
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature (2012) 3.80
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol (2011) 3.56
Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia. J Neurosci (2002) 3.50
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol (2013) 3.46
apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest (2008) 3.36
Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab (2006) 3.35
Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology (2007) 3.22
Sleep quality and preclinical Alzheimer disease. JAMA Neurol (2013) 3.11
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med (2009) 2.87
P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 2.81
Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science (2002) 2.78
Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci (2009) 2.76
CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J Neurosci (2009) 2.69
Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer's disease pathology. Sci Transl Med (2012) 2.66
A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci (2003) 2.63
Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2002) 2.58
Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science (2008) 2.53
Inflammation, microglia, and Alzheimer's disease. Neurobiol Dis (2009) 2.44
Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A (2008) 2.44
Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem (2012) 2.42
Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol (2009) 2.42
Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain (2005) 2.27
Loss of intranetwork and internetwork resting state functional connections with Alzheimer's disease progression. J Neurosci (2012) 2.26
Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann Neurol (2010) 2.25
Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci (2005) 2.21
The role of microglia in amyloid clearance from the AD brain. J Neural Transm (Vienna) (2010) 2.21
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology (2013) 2.19
ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem (2004) 2.19
Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci (2005) 2.18
Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci (2005) 2.17
Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem (2002) 2.13
GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron (2013) 2.13
Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol (2004) 2.08
Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc Natl Acad Sci U S A (2007) 2.06
Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am J Psychiatry (2006) 2.05
Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron (2009) 2.03
Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest (2008) 2.01
Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci (2008) 2.01
In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci (2011) 2.00
Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem (2006) 1.98
Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med (2011) 1.97
Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest (2005) 1.94
Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem (2005) 1.91
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) (2012) 1.90
Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J Neurosci (2005) 1.90
Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. Proc Natl Acad Sci U S A (2007) 1.89
Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. Brain (2012) 1.87
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol (2002) 1.86
Deletion of ERK2 mitogen-activated protein kinase identifies its key roles in cortical neurogenesis and cognitive function. J Neurosci (2008) 1.84
Relationship of dementia screening tests with biomarkers of Alzheimer's disease. Brain (2010) 1.80
Electromagnetic controlled cortical impact device for precise, graded experimental traumatic brain injury. J Neurotrauma (2007) 1.79
Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann Neurol (2003) 1.78
Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis (2002) 1.74
Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One (2011) 1.74
Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J Neurosci (2012) 1.71
Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann Neurol (2007) 1.70
IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci (2005) 1.69
Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol (2009) 1.68
Lysosomal sorting of amyloid-β by the SORLA receptor is impaired by a familial Alzheimer's disease mutation. Sci Transl Med (2014) 1.67
Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease. Neurobiol Dis (2006) 1.67
Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J Neurosci (2006) 1.65
The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J Biol Chem (2005) 1.63
PPARs in the brain. Biochim Biophys Acta (2007) 1.63
Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD. BMC Neurol (2006) 1.60
Cerebrospinal fluid Aβ42, phosphorylated Tau181, and resting-state functional connectivity. JAMA Neurol (2013) 1.60
YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry (2010) 1.59
Fibrillar beta-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia. J Biol Chem (2006) 1.59
SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet (2010) 1.58
Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J Neurosci (2003) 1.58